

Discover more from INSIDE PHARMA
Gene therapies been re-branded 'advanced therapies'—the feeding frenzy continues
Even FDAs top vaccine guy, Peter Marks, is in on it!
Keep getting this advanced therapy conference in my mailbox
Every few weeks, I get an email from Terrapinn, asking me to buy a ticket for their 2024 conference on advanced therapies. The speaker list is below:
Advanced Therapies 2024, 19-20th March, ExCeL London
Scroll down to speakers with the name beginning with ‘M’, and you will see Peter Marks M.D., PhD., Director - Center for Biologics Evaluation and Research (CBER) .
Marks is the person with delegated authority to evaluate and research applications to market new biologics drugs, eg vaccines.
Could this just be a teenty weeny conflict of interest?
Not at all, it’s a massive one!!!
It is also unprecedented for someone in his position to do anything other than fly-in for a Keynote Address, then fly out again. Hobobbing with the regulated was always a no-no.
What about the other speakers?
Now check out the other speakers. Take it from me, none of them have a clue about the complexities of manufacturing and distributing complex biologic products.
Then check out many of the companies—no more than a handful of employees with hopes of capitalising on the latest ‘market opportunity’.
I will leave you with the message I shared yesterday in relation to Lonza’s CEO being fired. Investors in gene therapies will lose their shirts if they keep placing their chips on mRNA injections that have been positioned as the next great white hope.
They. Are. Not.
Check below to discover how easy it is to be conned.
Gene therapies been re-branded 'advanced therapies'—the feeding frenzy continues
Anyone jumping on board now will lose their shirts as they have well and truly missed the Boom.😐 Like the tech dot.com bubble, by the time the opportunity was perceived at ground level, the bubble was bursting.😐😉
The pivot I believe the Pharma crowd will be moving to (especially given the growing push back on conventional treatments and tech) will be the traditional medicines- it's primed for pharma take over, given we have only explored 3-20% of ethnobotanics globally, WHO has just convened the 1st global trad medicines convention to help regulate and sustainably develop these systems, and with AI advancements, we can now sequence, process and extract therapeutics from botanicals, faster than ever before.
Especially with new justifications on patents and GMOs being upheld since 2012, allowing modified natural organisms to be patenable😐🤔🤨 Hence, we will see old Pharma pivot into natural medicines and with WHOs help, become "new pharma".🤔😉🤦♀️
#itsonlyjustbegun #oldisnew #naturevspatent
Makes sense to rename as these are not DNA altering, gene editing therapies.